Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered virus targets Hard-to-Treat blood cancers in new trial

NCT ID NCT03017820

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is designed to infect and kill cancer cells while protecting healthy cells. The main goal is to find the safest dose and understand side effects. About 99 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma B-cell neoplasm B-cell non-Hodgkin lymphoma histiocytic and dendritic cell neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides myelodysplastic syndrome Myelodysplastic Syndromes peripheral T-cell lymphoma, not otherwise specified plasma cell myeloma primary cutaneous T-cell non-Hodgkin lymphoma refractory plasma cell neoplasm T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA HISTIOCYTIC AND DENDRITIC CELL NEOPLASM MYELODYSPLASTIC SYNDROME PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME RECURRENT ADULT ACUTE MYELOID LEUKEMIA RECURRENT ANAPLASTIC LARGE CELL LYMPHOMA RECURRENT ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA RECURRENT MYCOSIS FUNGOIDES RECURRENT PLASMA CELL MYELOMA RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA RECURRENT T-CELL NON-HODGKIN LYMPHOMA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA REFRACTORY MYCOSIS FUNGOIDES REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY PLASMA CELL MYELOMA REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY T-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact